On June 22, 2026, the Trump administration and HHS Secretary Robert F. Kennedy Jr. announce sweeping regulatory reforms to modernize and accelerate clinical trials. The FDA initiative aims to cut six months to a year off early-stage safety studies. This policy responds to pharmaceutical industry demands and seeks to counter competition from China and Australia, where faster regulatory timelines have driven U.S. companies to invest abroad and acquire Chinese biotechs.
Clinical trial modernization reforms
- ▪On June 22, 2026, United States federal health officials unveiled regulatory reforms aimed at cutting six months to a year off safety study timelines
- ▪The Food and Drug Administration regulatory reforms target safety studies, which represent the first round of testing new drugs in humans
U.S.-China biotech competition
- ▪Pharmaceutical companies increasingly conduct early drug research in China and Australia to reduce the time and financial costs of clinical testing
- ▪United States drug companies are actively purchasing Chinese biotechnology firms, frequently citing the speed of China's regulatory authorities
Trump administration drug development policy
- ▪The Trump administration designed its clinical trial reforms in response to calls from the biotechnology and pharmaceutical industries to modernize drug testing
- ▪Department of Health and Human Services Secretary Robert F. Kennedy Jr. announced clinical trial reforms on June 22, 2026, to counter competition from China
Story comments
Loading comments…